TME Pharma N.V. (EPA:ALTME)

France flag France · Delayed Price · Currency is EUR
0.0644
-0.0016 (-2.42%)
Apr 24, 2025, 3:46 PM CET
-74.89%
Market Cap 6.21M
Revenue (ttm) n/a
Net Income (ttm) -6.33M
Shares Out 94.12M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 187,455
Average Volume 208,129
Open 0.0670
Previous Close 0.0660
Day's Range 0.0641 - 0.0670
52-Week Range 0.0592 - 0.2700
Beta 1.81
RSI 43.01
Earnings Date Apr 23, 2025

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 13
Stock Exchange Euronext Paris
Ticker Symbol ALTME
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.